The changing landscape of axillary surgery: Which breast cancer patients may still benefit from complete axillary lymph node dissection?

Journal of Surgical Oncology

Volumn 106, Issue 3, 2012, Pages 254-259

  McGhan, L J ^a   Dueck, A C ^a   Gray, R J ^a   Wasif, N ^a   McCullough, A E ^a   Pockaj, B A ^a  

^a MAYO CLINIC   (United States)

Author keywords

completion axillary lymph node dissection; frozen section; non sentinel lymph node metastases; predictive model; sentinel lymph node biopsy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; AGED; ALGORITHM; ARTICLE; ASPIRATION BIOPSY; AXILLARY LYMPH NODE; BODY MASS; BREAST CANCER; CANCER INVASION; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; COMPLETION AXILLARY LYMPH NODE DISSECTION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FROZEN SECTION; HIGH RISK PATIENT; HUMAN; IMMUNOHISTOCHEMISTRY; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MASTECTOMY; MICROMETASTASIS; PREDICTIVE VALUE; PRIORITY JOURNAL; SENTINEL LYMPH NODE METASTASIS; SURGICAL APPROACH; THERAPY DELAY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; AXILLA; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPH NODE EXCISION; LYMPHATIC METASTASIS; MIDDLE AGED; RECEPTOR, ERBB-2; RETROSPECTIVE STUDIES; RISK ASSESSMENT;

EID: 84864677308     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22131     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, et al.: Cancer Statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Beenken SW, Urist NM, Zhang Y, et al.: Axillary lymph node status, but not overall tumor size, predicts locoregional recurrence and overall survival after mastectomy for breast cancer. Ann Surg 2003; 237: 732-738.
3. Quiet CA, Ferguson DJ, Weichselbaum RR, et al.: Natural history of node-negative breast cancer: A study of 826 patients with long-term follow-up. J Clin Oncol 1995; 13: 1144-1151.
4. Schwartz GF,: Clinical practice guidelines for the use of axillary sentinel lymph node biopsy in carcinoma of the breast: Current update. Breast J 2004; 10: 85-88.
5. Lyman GH, Giuliano AE, Somerfield MR, et al.: American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol 2005; 23: 7703-7720.
6. Veronesi U, Paganelli G, Viale G, et al.: Sentinel-lymph-node biopsy as a staging procedure in breast cancer: Update of a randomised controlled study. Lancet Oncol 2006; 7: 983-990.
7. Takei H, Kurosumi M, Yoshida T, et al.: Current trends of sentinel lymph node biopsy for breast cancerA surgeon's perspective. Breast Cancer 2007; 14: 362-370.
8. Cheng G, Kurita S, Torigian DA, et al.: Current status of sentinel lymph-node biopsy in patients with breast cancer. Eur J Nucl Med Mol Imaging 2011; 38: 562-575.
9. Chen JJ, Wu J,: Management strategy of early-stage breast cancer patients with a positive sentinel lymph node: With or without axillary lymph node dissection. Crit Rev Oncol Hematol 2010; 79: 293-301.
10. Barbosa EM, Francisco AA, Araujo Neto JT, et al.: Clinicopathological predictor factors of axillary involvement in patients with metastatic breast cancer in the sentinel lymph node. Rev Bras Ginecol Obstet 2010; 32: 144-149.
11. Jeong JH, Anderson S, Bryant J, et al.: Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002; 347: 567-575.
12. Giuliano AE, Hunt KK, Ballman KV, et al.: Axillary dissection vs. no axillary dissection in women with invasive breast cancer and sentinel node metastasis: A randomized clinical trial. JAMA 2011; 305: 569-575.
13. Alran S, De Rycke Y, Fourchotte V, et al.: Validation and limitations of use of a breast cancer nomogram predicting the likelihood of non-sentinel node involvement after positive sentinel node biopsy. Ann Surg Oncol 2007; 14: 2195-2201.
14. Gur AS, Unal B, Ozbek U, et al.: Validation of breast cancer nomograms for predicting the non-sentinel lymph node metastases after a positive sentinel lymph node biopsy in a multi-center study. Eur J Surg Oncol 2010; 36: 30-35.
15. Sanjuán A, Escaramís G, Vidal-Sicart S, et al.: Predicting non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement: Evaluation of two scoring systems. Breast J 2010; 16: 134-140.
16. Coutant C, Morel O, Antoine M, et al.: Is axillary lymph node dissection always necessary in breast cancer patients with a positive sentinel node? J Chir (Paris) 2007; 144: 492-501.
17. Hwang RF, Krishnamurthy S, Hunt KK, et al.: Clinicopathologic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer. Ann Surg Oncol 2003; 10: 248-254.
18. Barranger E, Coutant C, Flahault A, et al.: An axilla scoring system to predict non-sentinel lymph node status in breast cancer patients with sentinel lymph node involvement. Breast Cancer Res Treat 2005; 91: 113-119.
19. Kohrt HE, Olshen RA, Bermas HR, et al.: New models and online calculator for predicting non-sentinel lymph node status in sentinel lymph node positive breast cancer patients. BMC Cancer 2008; 8: 66.
20. Pal A, Provenzano E, Duffy SW, et al.: A model for predicting non-sentinel lymph node metastatic disease when the sentinel lymph node is positive. Br J Surg 2008; 95: 302-309.
21. Van Zee KJ, Manasseh DM, Bevilacqua JL, et al.: A Nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel lymph node biopsy. Ann Surg Oncol 2003; 10: 1140-1151.
22. Unal B, Gur AS, Kayiran O, et al.: Models for predicting non-sentinel lymph node positivity in sentinel node positive breast cancer: The importance of scoring system. Int J Clin Pract 2008; 62: 1785-1791.
23. Poirier E, Sideris L, Dubé P, et al.: Analysis of clinical applicability of the breast cancer nomogram for positive sentinel lymph node: The Canadian experience. Ann Surg Oncol 2008; 15: 2562-2567.
24. Dauphine CE, Haukoos JS, Vargas MP, et al.: Evaluation of three scoring systems predicting non sentinel node metastasis in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2007; 14: 1014-1019.
25. Coutant C, Olivier C, Lambaudie E, et al.: Comparison of models to predict nonsentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: A prospective multicenter study. J Clin Oncol 2009; 27: 2800-2808.
26. Cyr A, Gillanders WE, Aft RL, et al.: Micrometastatic disease and isolated tumor cells as a predictor for additional breast cancer axillary metastatic burden. Ann Surg Oncol 2010; 7: 303-311.
27. van de Vrande S, Meijer J, Rijnders A, et al.: The value of intraoperative frozen section examination of sentinel lymph nodes in breast cancer. Eur J Surg Oncol 2009; 35: 276-280.
28. Tille JC, Egger JF, Devillaz MC, et al.: Frozen section in axillary sentinel lymph nodes for diagnosis of breast cancer micrometastasis. Anticancer Res 2009; 29: 4711-4716.
29. Liu LC, Lang JE, Lu Y, et al.: Intraoperative frozen section analysis of sentinel lymph nodes in breast cancer patients: A meta-analysis and single-institution experience. Cancer 2011; 17: 250-258.
30. Dabbs DJ, Fung M, Landsittel D, et al.: Sentinel lymph node micrometastasis as a predictor of axillary tumor burden. Breast J 2004; 10: 101-105.
31. Langer I, Guller U, Berclaz G, et al.: Accuracy of frozen section of sentinel lymph nodes; a prospective analysis of 659 breast cancer patients of the Swiss multicenter study. Breast Cancer Res Treat 2009; 113: 129-136.
32. Reed J, Rosman M, Verbanac KM, et al.: Prognostic implications of isolated tumor cells and micrometastases in sentinel nodes of patients with invasive breast cancer. J Am Coll Surg 2009; 208: 333-340.
33. Ozcinar B, Muslumanoglu M, Igci A, et al.: Clinical importance of micrometastasis in sentinel lymph nodes. Breast 2011; 20: 31-33.
34. Meretoja TJ, Vironen JH, Heikkilä PS, et al.: Outcome of selected breast cancer patients with micrometastasis or isolated tumor cells in sentinel node biopsy and no completion axillary lymph node dissection. J Surg Oncol 2010; 102: 215-219.
35. Yegiyants S, Romero LM, Haigh PI, et al.: Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node. Arch Surg 2010; 145: 564-569.
36. Pernas S, Gil M, Benítez A, et al.: Avoiding axillary treatment in sentinel lymph node micrometastases of breast cancer: A prospective analysis of axillary or distant recurrence. Ann Surg Oncol 2010; 17: 772-777.
37. de Boer M, van Deurzen CHM, van Dijck JAAM, et al.: Micrometastases or isolated tumor cells and the outcome of breast cancer. N Engl J Med 2009; 361: 653-663.
38. Hansen NM, Grube B, Ye X, et al.: Impact of micrometastases in the sentinel lymph node of patients with invasive breast cancer. J Clin Oncol 2009; 27: 4679-4684.
39. Weaver DL, Ashikaga T, Krag DN, et al.: Effect of occult metastases on survival in node-negative breast cancer. N Engl J Med 2011; 364: 412-421.
40. Giuliano AE, McCall L, Beitsch P, et al.: Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: The American College of Surgeons Oncology Group Z0011 randomized trial. Ann Surg 2010; 252: 426-432.
41. Krishnamurthy S, Sneige N, Bedi DG, et al.: Role of ultrasound-guided fine-needle aspiration of indeterminate and suspicious axillary lymph nodes in the initial staging of breast cancer. Cancer 2002; 95: 982-988.
42. van Rijk MC, Deurloo EE, Nieweg OE, et al.: Ultrasonography and fine-needle aspiration cytology can spare breast cancer patients unnecessary sentinel lymph node biopsy. Ann Surg Oncol 2006; 13: 31-35.